Q-omics provides the consensus-scored TRIM72 profile across patient tissues and cancer cell-line models. TRIM72 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM72 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TRIM72 protein abundance shows 9,901 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where TRIM72 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM72 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM72 survival associations across molecular data types. TRIM72 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM72 RNA expression–survival associations across cancer types. High TRIM72 expression shows unfavorable associations in KIRC, LIHC, ACC, KIRP and THCA, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM72 RNA expression.
This table summarizes TRIM72 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM72. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM72 shows lower tumor expression in KIRP and higher tumor expression in COAD, BRCA, LUSC, LUAD and LIHC. The COAD box plot shows higher TRIM72 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with TRIM72 in patient tissues and cancer cell lines. In patient samples, TRIM72 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM72 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
